Caribou Biosciences (NASDAQ:CRBU) Cut to Neutral at HC Wainwright

HC Wainwright downgraded shares of Caribou Biosciences (NASDAQ:CRBU) from a buy rating to a neutral rating in a research report released on Thursday morning, MarketBeat reports. HC Wainwright also issued estimates for Caribou Biosciences’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.05) EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Caribou Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Leerink Partners reaffirmed a “market perform” rating and set a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a research report on Wednesday. Brookline Capital Markets cut shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. Finally, Bank of America lowered their target price on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.50.

Caribou Biosciences Trading Down 4.4%

Caribou Biosciences stock opened at $0.46 on Thursday. Caribou Biosciences has a 12 month low of $0.44 and a 12 month high of $3.54. The stock’s 50 day moving average is $1.41 and its 200-day moving average is $1.73. The company has a market capitalization of $49.34 million, a price-to-earnings ratio of -0.43 and a beta of 2.31.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. The business had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.28 million. As a group, equities research analysts predict that Caribou Biosciences will post -1.07 earnings per share for the current fiscal year.

Institutional Trading of Caribou Biosciences

Large investors have recently modified their holdings of the stock. CTC Alternative Strategies Ltd. bought a new position in shares of Caribou Biosciences in the first quarter worth $29,000. Next Capital Management LLC bought a new stake in Caribou Biosciences during the second quarter worth about $35,000. Westmount Partners LLC acquired a new stake in Caribou Biosciences during the first quarter worth about $37,000. The Manufacturers Life Insurance Company acquired a new stake in Caribou Biosciences during the second quarter worth about $41,000. Finally, Spark Investment Management LLC bought a new position in Caribou Biosciences in the 2nd quarter valued at about $42,000. 77.51% of the stock is owned by institutional investors and hedge funds.

More Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Leerink Partners set a $1.00 price target, substantially above the recent trading level, suggesting potential upside if Caribou’s clinical and business outlook improves. However, the firm simultaneously downgraded the stock to “Market Perform.” Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Neutral Sentiment: HC Wainwright downgraded Caribou from “Buy” to “Neutral” and issued forecasts for continued losses through 2027: $(0.11) EPS in the first quarter, $(0.08) in the second, $(0.07) in the third and $(0.05) in the fourth. The estimates imply gradual improvement but no near-term profitability. HC Wainwright Downgrades Caribou Biosciences to Neutral
• Neutral Sentiment: Reported short interest totaled zero shares as of October 9, producing a zero-day days-to-cover ratio. This indicates no measurable short-position overhang in the reported data, although the figure may reflect a reporting anomaly rather than a meaningful change in investor positioning.
• Negative Sentiment: Brookline Capital Markets also downgraded Caribou to “Hold,” adding to the recent wave of more cautious analyst opinions. Brookline Capital Markets Downgrades Caribou Biosciences to Hold
• Negative Sentiment: A MedCity News report described Caribou’s off-the-shelf cell-therapy effort as reaching the “end of the road,” raising concerns about the company’s pipeline, future catalysts and ability to create shareholder value. Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.